Mary Jenkins | Associate Director-Investor Relations |
Doug Ingram | President and Chief Executive Officer |
Louise Rodino-Klapac | Executive Vice President, Head-R&D and Chief Scientific Officer |
Dallan Murray | Executive Vice President and Chief Customer Officer |
Ian Estepan | Executive Vice President and Chief Financial Officer |
Colin Bristow | UBS |
Gena Wang | Barclays |
Brian Abrahams | RBC Capital Markets |
Judah Frommer | Credit Suisse |
Salveen Richter | Goldman Sachs |
Gil Blum | Needham and Company |
Tazeen Ahmad | Bank of America |
Danielle Brill | Raymond James |
Mike Ulz | Morgan Stanley |
Neena Bitritto-Garg | Citi |
Tim Lugo | William Blair |
Kristen Kluska | Cantor Fitzgerald |
Hartaj Singh | Oppenheimer and Company |
Debjit Chattopadhyay | Guggenheim |
Joseph Schwartz | SVB Securities |
Zhiqiang Shu | Berenberg |
Gavin Clark-Gartner | Evercore ISI |
Brian Skorney | Baird |
Anupam Rama | JPMorgan |
Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2023 Earnings Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator instructions] As a reminder, today's program is being recorded.
At this time, I will turn the call over to Mary Jenkins, Associate Director, Investor Relations.